FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891493655> ?p ?o ?g. }

• W2891493655 abstract "4126 Background: Concerns have been raised on the risk of pancreatic cancer associated with specific anti-diabetic therapies. We have examined the risk of pancreatic cancer among patients with diabetes prescribed with an oral anti-diabetic drug (OAD) or an incretin drug (DPP4i and GLP-1 RA) or insulin. Methods: The public health insurance databases of Belgium and of Lombardy Region, Italy include nearly 100% of the population living in these countries. We created within these databases two cohorts that included adult patients who were first prescribed an incretin drug or another noninsulin antidiabetic drug (NIAD) during 01/07/2008-31/12/2013 in Belgium and during 01/01/2008-31/12/2012 in Lombardy Region. The risk of pancreatic cancer after prescription of an anti-diabetic drug was evaluated using multivariate adjusted Cox models including time-dependent variables. Adjusted hazard ratios (aHRs) from Belgium and Italy were pooled using fixed effects meta-analyses. Results: Results in both cohorts were similar. Among those patients prescribed an OAD, 45% of pancreatic cancers occurred within the 6 months following first prescription, 20% in months 7 to 12 after first prescription and proportions decreased progressively during follow-up. The aHR of pancreatic cancer among subjects prescribed an incretin compared to an OAD was 2.14 [95% CI, 1.71 to 2.67]. The aHR decreased from 3.35 [CI, 2.32 to 4.84] in the first 3 months after first incretin prescription, 2.12 [CI, 1.22 to 3.66] in months 3 to 5.9, 1.95 [CI, 1.20 to 3.16] in months 6 to 11.9, to 1.69 [CI, 1.12 to 2.55] after 12 months. The risk of pancreatic cancer among subjects who were subsequently prescribed insulin was 6.89 [CI, 6.05 to 7.85]. The time from OAD prescription to a shift to incretins or to insulin was significantly lower in patients who were subsequently diagnosed with a pancreatic cancer. Conclusions: The increased risk of pancreatic cancer associated with anti-diabetic therapies could be the consequence of an occult pancreatic cancer that provokes diabetes (reverse causation bias). The search for an occult pancreatic cancer in subjects with newly diagnosed diabetes or patients shifting to more potent anti-diabetic therapy may lead to earlier detection of this cancer." @default.
• W2891493655 created "2018-09-27" @default.
• W2891493655 creator A5000713732 @default.
• W2891493655 creator A5011749185 @default.
• W2891493655 creator A5017118745 @default.
• W2891493655 creator A5022257735 @default.
• W2891493655 creator A5024764499 @default.
• W2891493655 creator A5041154078 @default.
• W2891493655 creator A5045075334 @default.
• W2891493655 creator A5048235992 @default.
• W2891493655 creator A5055739306 @default.
• W2891493655 creator A5066156065 @default.
• W2891493655 date "2017-05-20" @default.
• W2891493655 modified "2023-09-23" @default.
• W2891493655 title "Initiation and shift of antidiabetic therapy and pancreatic cancer." @default.
• W2891493655 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.4126" @default.
• W2891493655 hasPublicationYear "2017" @default.
• W2891493655 type Work @default.
• W2891493655 sameAs 2891493655 @default.
• W2891493655 citedByCount "0" @default.
• W2891493655 crossrefType "journal-article" @default.
• W2891493655 hasAuthorship W2891493655A5000713732 @default.
• W2891493655 hasAuthorship W2891493655A5011749185 @default.
• W2891493655 hasAuthorship W2891493655A5017118745 @default.
• W2891493655 hasAuthorship W2891493655A5022257735 @default.
• W2891493655 hasAuthorship W2891493655A5024764499 @default.
• W2891493655 hasAuthorship W2891493655A5041154078 @default.
• W2891493655 hasAuthorship W2891493655A5045075334 @default.
• W2891493655 hasAuthorship W2891493655A5048235992 @default.
• W2891493655 hasAuthorship W2891493655A5055739306 @default.
• W2891493655 hasAuthorship W2891493655A5066156065 @default.
• W2891493655 hasConcept C121608353 @default.
• W2891493655 hasConcept C126322002 @default.
• W2891493655 hasConcept C134018914 @default.
• W2891493655 hasConcept C143998085 @default.
• W2891493655 hasConcept C2780210213 @default.
• W2891493655 hasConcept C555293320 @default.
• W2891493655 hasConcept C71924100 @default.
• W2891493655 hasConceptScore W2891493655C121608353 @default.
• W2891493655 hasConceptScore W2891493655C126322002 @default.
• W2891493655 hasConceptScore W2891493655C134018914 @default.
• W2891493655 hasConceptScore W2891493655C143998085 @default.
• W2891493655 hasConceptScore W2891493655C2780210213 @default.
• W2891493655 hasConceptScore W2891493655C555293320 @default.
• W2891493655 hasConceptScore W2891493655C71924100 @default.
• W2891493655 hasLocation W28914936551 @default.
• W2891493655 hasOpenAccess W2891493655 @default.
• W2891493655 hasPrimaryLocation W28914936551 @default.
• W2891493655 hasRelatedWork W1686031945 @default.
• W2891493655 hasRelatedWork W186447804 @default.
• W2891493655 hasRelatedWork W2056365318 @default.
• W2891493655 hasRelatedWork W2080762973 @default.
• W2891493655 hasRelatedWork W2101887074 @default.
• W2891493655 hasRelatedWork W2149748796 @default.
• W2891493655 hasRelatedWork W2279233597 @default.
• W2891493655 hasRelatedWork W2331103872 @default.
• W2891493655 hasRelatedWork W2334614958 @default.
• W2891493655 hasRelatedWork W2335669898 @default.
• W2891493655 hasRelatedWork W2382368291 @default.
• W2891493655 hasRelatedWork W2412857382 @default.
• W2891493655 hasRelatedWork W264574363 @default.
• W2891493655 hasRelatedWork W2763436959 @default.
• W2891493655 hasRelatedWork W2809152602 @default.
• W2891493655 hasRelatedWork W2921280962 @default.
• W2891493655 hasRelatedWork W2924457271 @default.
• W2891493655 hasRelatedWork W2943997826 @default.
• W2891493655 hasRelatedWork W3036633985 @default.
• W2891493655 hasRelatedWork W3165301899 @default.
• W2891493655 isParatext "false" @default.
• W2891493655 isRetracted "false" @default.
• W2891493655 magId "2891493655" @default.
• W2891493655 workType "article" @default.